Empreendimentos Pague Menos (PGMN3) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
6 Nov, 2026Executive summary
3Q26 gross revenue rose 6.9% YoY to R$4.429bn; same-store sales grew 5.6%.
Adjusted EBITDA was R$278.8m, up 7.2%, with a 6.3% margin; adjusted net income rose 19.5% to R$96.3m.
Operational cash flow reached R$164.8m, more than 3x 3Q25, while adjusted net debt/EBITDA declined to 1.8x from 2.5x.
Growth priorities included continuous-care clients, digital channels, private labels and AI-enabled customer engagement.
Financial highlights
9M26 gross revenue grew 10.0% to R$12.916bn; adjusted EBITDA rose 16.9% to R$765.2m and adjusted net income rose 46.5% to R$225.5m.
Q3 gross profit increased 7.2% to R$1.327bn; gross margin reached 30.0%, up 0.1 p.p. YoY and the highest Q3 level since 2018.
Q3 adjusted net margin expanded 0.3 p.p. to 2.2%; contribution margin was 8.6%, down 0.2 p.p.
Selling expenses rose 8.5% to R$946m; growth was 7.4% excluding R$9.6m of one-off severance costs.
Financial result expense fell 13.0% YoY to R$112.7m.
Outlook and guidance
More than 20 stores were in advanced development for Q4 openings; expansion is focused on North and Northeast regions and popular-income areas.
Cash-cycle days and supplier payment terms are expected to recover in Q4 as replenishment normalizes and sales stabilize.
Q4 preparations included tactical inventory build-up, particularly in GLP-1, and accelerated investment ahead of increased store openings.
Profitability initiatives include expense controls, digital conversion, private-label penetration, CRM and productivity improvements.
Latest events from Empreendimentos Pague Menos
- Record profitability, strong digital growth, and continued deleveraging and market share gains.PGMN3
Q2 2026 - Revenue up 14.4% YoY, net income quadrupled, and digital sales surged to 22.2% of total.PGMN3
Q1 2026 - 2025 saw record revenue, EBITDA, and net income, with market share and digital sales at all-time highs.PGMN3
Q4 2025 - Record 18% revenue growth, 49.6% net income rise, and 6.7% market share in 3Q25.PGMN3
Q3 2025 - Record sales and digital growth drove higher margins, profit, and market share gains.PGMN3
Q2 2025 - Record sales, margin gains, and cash flow driven by Extrafarma synergies and digital growth.PGMN3
Q3 2024 - Revenue and profit surged as growth accelerated, cash flow improved, and market share increased.PGMN3
Q2 2024 - Record revenue, EBITDA, and digital sales drove margin gains and market share growth in 1Q25.PGMN3
Q1 2025 - Record sales, margin expansion, and synergy gains drive robust growth and deleveraging.PGMN3
Q4 2024